Alcohol is a major contributor to global disease and a leading cause of preventable death,
causing approximately 88,000 deaths annually in the United States alone. Alcohol use …

This article proposes a heuristic framework for the Addictions Neuroclinical Assessment that
incorporates key functional domains derived from the neurocircuitry of addiction. We review …

Background: Alcohol use disorder (AUD) and its associated consequences remain
significant public health concerns. Given that AUD represents a spectrum of severity …

Chronic heavy alcohol use impacts all major neurotransmitter systems and is associated
with multiple medical, psychiatric, and social problems. Available evidence‐based …

Pathologic alcohol use affects more than 2 billion people and accounts for nearly 6% of all
deaths worldwide. There are three medications approved for the treatment of alcohol use …

Randomized trials of medications for alcohol dependence (AD) often report no differences
between active medications. Few studies in AD have tested hypotheses regarding which …

Naltrexone is a semi-synthetic opioid with competitive antagonist activity at mu opioid
receptors. Its efficacy has been demonstrated in the treatment of alcohol and opioid …

Addiction remains a major public health concern, and while pharmacotherapies can be
effective, clinicians are limited by the paucity of existing interventions. Endocannabinoid …

Introduction: Only a few medications are available for the treatment of alcohol use disorders
(AUDs). Areas covered: This paper discusses approved AUD medications, including the …

Naltrexone reduces drinking among individuals with alcohol use disorders (AUDs), but it is
not effective for everyone. Variability in its effects on reward-related brain activation, genetic …